The Challenge of Yeztugo: Navigating New HIV Prevention Landscapes

Yeztugo, a biannual injection from Gilead Sciences for HIV prevention, has faced hurdles despite a promising start. While insurers cover most patients, issues like co-payments, coverage gaps, and patient preferences for daily pills contribute to its slow uptake. Nonetheless, Yeztugo shows promise for changing HIV prevention dynamics.

Gilead Sciences' new HIV prevention injection, Yeztugo, launched in June and has seen growing use. However, challenges persist as some patients encounter insurance hurdles and prefer daily pills over biannual shots.

Yeztugo has been approved as nearly 100% effective in preventing HIV. Despite initial excitement, the number of people opting for it is below expectations. Gilead's competitors offer alternative PrEP options like daily pills Descovy and Truvada.

The rise in telehealth services and patient concerns, such as fear of needles, contribute to the slow uptake. Analysts predict substantial growth in Yeztugo's sales, but reaching uninsured patients and convincing current pill users remains a complex task.